Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
The Lancet. Haematology
|
July 18, 2025
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial
Vania Hungria, Marek Hus, ChengCheng Fu, et al.
The Lancet. Haematology
|
October 4, 2023
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
Meletios Athanasios Dimopoulos, Vania T M Hungria, Atanas Radinoff, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 13, 2015
Prevalence and Incidence of Respiratory Syncytial Virus and Other Respiratory Viral Infections in Children Aged 6 Months to 10 Years With Influenza-like Illness Enrolled in a Randomized Trial
Terry Nolan, Charissa Borja-Tabora, Pio Lopez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma
Danny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.
The Journal of Infection
|
September 27, 2016
Respiratory viruses and influenza-like illness: Epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample
Sylvia Taylor, Pio Lopez, Lily Weckx, et al.
The Journal of Infectious Diseases
|
March 22, 2014
Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial
Terry Nolan, Sumita Roy-Ghanta, May Montellano, et al.
The Lancet. Oncology
|
July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Vania Hungria, Paweł Robak, Marek Hus, et al.
The New England Journal of Medicine
|
June 3, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Vania Hungria, Pawel Robak, Marek Hus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2021
Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance
Carol Durno, Ayse Bahar Ercan, Vanessa Bianchi, et al.
The Lancet. Oncology
|
March 29, 2024
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study
Ayse Bahar Ercan, Melyssa Aronson, Nicholas R Fernandez, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
The Lancet. Haematology
|
July 18, 2025
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial
Vania Hungria, Marek Hus, ChengCheng Fu, et al.
The Lancet. Haematology
|
October 4, 2023
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
Meletios Athanasios Dimopoulos, Vania T M Hungria, Atanas Radinoff, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 13, 2015
Prevalence and Incidence of Respiratory Syncytial Virus and Other Respiratory Viral Infections in Children Aged 6 Months to 10 Years With Influenza-like Illness Enrolled in a Randomized Trial
Terry Nolan, Charissa Borja-Tabora, Pio Lopez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma
Danny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.
The Journal of Infection
|
September 27, 2016
Respiratory viruses and influenza-like illness: Epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample
Sylvia Taylor, Pio Lopez, Lily Weckx, et al.
The Journal of Infectious Diseases
|
March 22, 2014
Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial
Terry Nolan, Sumita Roy-Ghanta, May Montellano, et al.
The Lancet. Oncology
|
July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Vania Hungria, Paweł Robak, Marek Hus, et al.
The New England Journal of Medicine
|
June 3, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Vania Hungria, Pawel Robak, Marek Hus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2021
Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance
Carol Durno, Ayse Bahar Ercan, Vanessa Bianchi, et al.
The Lancet. Oncology
|
March 29, 2024
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study
Ayse Bahar Ercan, Melyssa Aronson, Nicholas R Fernandez, et al.
Page
of 6